Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Medivir to present at the Erik Penser Bank Health Care Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that its new CEO Jens Lindberg will participate at the Erik Penser Bank Health Care Day, Thursday February 24, 2022. Jens Lindberg took office at Medivir on January 24, 2022. He will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (formerly MIV-818).     The presentation will be available after the meeting on Medivirs website; www.medivir.com.     For additional information, please contact Magnus Christensen, CFO, Medivir AB Telephone: +46 8 5468

Year-End report January – December 2021

Fourth quarter in brief · Net sales amounted to 18.4 million SEK (15.8), which means a sales growth of 16 percent. · Operating profit amounted to 5.2 million SEK (3.1). · Net profit for the period amounted to 3.1 million SEK (3.0). · Earnings per share amounted to 0.08 SEK (0.07). Full year January - December in brief · Net sales for the full year 2021 amounted to 58.4 million SEK (48.7), which means a sales growth of 20 percent. ·Operating profit amounted to 10.0 million SEK (0.9). ·Profit for the period amounted to 7.9 million SEK (0.7). ·

XNK Therapeutics to present at Redeye’s Regenerative Medicine/Cell Therapy event on February 23

XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 23 at 09.50 CET. The presentation is broadcasted live and can be followed at: https://www.redeye.se/events/825130/redeye-theme-regenerative-medicine-cell-therapyThe presentation will be available online on XNK Therapeutics’ website https://xnktherapeutics.com shortly after the event. For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail: johan.liwing@xnktherapeutics.com About XNK Therapeutics AB XNK

Year-end report 1 January – 31 December 2021

Continued strong growth in net sales and operating profit, acquisition in BelgiumFOURTH QUARTER 2021 · Net sales increased by 86 percent to MSEK 206 (111). In unchanged currency levels, net sales increased by 86 percent. · Operating profit after depreciation/amortization increased by 62 percent to MSEK 15 (9.4) including negative currency effects of MSEK -0.6 (0.9). Operating profit was negatively impacted by direct acquisition costs of MSEK -0.8. · Cash flow from operating activities amounted to MSEK -8 (21). · Earnings per share increased to SEK 0.60 (0.38). · Solidity

Fourth quarter & Year-end report 2021 for BPC Instruments AB

BPC Instruments (“BPC” or “the Company”) hereby publishes the year-end report for the period 1 October – December 31, 2021. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.2021-10-01 - 2021-12-31 (fourth quarter) · Net sales for the quarter amounted to 9,2 MSEK (10,4 MSEK) · Net profit for the quarter amounted to 2,7 MSEK (3,5 MSEK) · Earnings per share for the quarter amounted to SEK 0,26 (SEK 0,36*) 2021-01-01 - 2021-12-31 (financial year, twelve months) · Net sales for the year amounted

Modus Therapeutics publishes year-end report for 2021

STOCKHOLM, SWEDEN - 22 February 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes a year-end report for 2021. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the year-end report.John Öhd, Modus Therapeutics' CEO, commented:  "This has been a transformative year for Modus, as we set out and executed on our new strategy to focus sevuparin development on sepsis, launched our oversubscribed IPO on First North, and rapidly progressed into a Phase 1b clinical trial that evaluates sevuparin during LPS

Year-end report January – December 2021: Catena stands stronger than ever

Record profit for 2021, a continued stable cash flow trend and strong growth in value mean that Catena can continue to grow and to drive the development of the Scandinavian logistics property market.22 February 2022, 8.00 a.m. · Rental income rose by 10 percent to SEK 1,387.4 million (1,263.9). · The net operating surplus increased by 9 percent to SEK 1,095.4 million (1,003.8). · Profit from property management rose by 15 percent to SEK 824.1 million (718.6). · Changes in the values of properties and derivatives amounted to SEK 2,542.4 million (1,204.9). · Profit for the

Embellence Group Year-end report 2021

Solid finish to a strong 2021Fourth quarter of 2021 · Net sales amounted to MSEK 174.0 (166.1), up 4.8%. · EBITA amounted to MSEK 25.8 (21.0), up 22.9% · Adjusted EBITA amounted to MSEK 30.4 (30.0), up 1.3%. · Net profit for the quarter amounted to MSEK 18.4 (9.9), and earnings per share before dilution to SEK 0.86 (0.46). · Operating cash flow amounted to MSEK 15.2 (19.5) · The equity ratio amounted to 47.1% (41.3) Significant events during the quarter · Pappelina acquired two production facilities · Organisational and legal changes at Boråstapeter · Lotta

Full year report January - December 2021, an eventful year with yet another strong quarter

Financial highlights October – December 2021                                                                                             · Net sales increased by 41.6 percent to EUR 44.8m (31.6). Organic growth excluding currency effects was 27.6 percent  · Gross profit amounted to EUR 22.7m (16.4) with a gross margin of 50.8 percent (52.1) · Adjusted EBITDA amounted to EUR 8.5m (5.5) with an adjusted EBITDA margin of 19.0 percent (17.5). Adjusted EBITDA, excluding the FX effect from the revaluation of operating balance sheet items, amounted to EUR 7.9m (5.9) and the margin 17.6

OssDsign AB (publ) publishes Year-end Report 2021

Another sales record marks the end of a transformative year for OssDsign.The fourth quarter in figures · Net sales amounted to TSEK 9,174 (6,760). · Loss after taxes amounted to TSEK 28,726 (24,952). · Earnings per share was SEK -0.5 (-1.1). · Cash flow from current operations was TSEK -20,456 (-24,266).   The full year in figures · Net sales amounted to TSEK 31,726 (24,872). · Loss after taxes amounted to TSEK 94,077 (84,590). · Earnings per share was SEK -1.9 (-4.4). · Cash flow from current operations was TSEK -89,629 (-79,331).   Important events

Eurobattery Minerals continuing to realize its business strategy - publishes year-end report January – December 2021

Stockholm, 22nd of February 2022 – Eurobattery Minerals started and completed a new drilling campaign in its Finnish Hautalampi project in the fourth quarter. In addition, the company completed a drilling campaign in the Spanish Corcel project and, at the beginning of Q1 2022, obtained initial results from the same battery mineral project, indicating a 60 million tonnes mineral reserve with 0.25% nickel. Further to this, the company joined two important sustainability collaborations. With this, the company continues to realize its business strategy providing European mined battery minerals

Invitation to the presentation of Ranplan’s Annual Statement 2021

Stockholm, Sweden, 22 February 2022 - Ranplan Group AB is pleased to invite media, investors, shareholders and financial analysts to a video conference presentation from its office in the city of Stockholm. On this occasion, CEO Per Lindberg and CSO Jon Ullmark will present the Annual Statement for 2021. Those who want to participate online at this event should notify the company of their interest before 6pm CET on 23 February 2022 by sending an e-mail to joyce.wu@ranplanwireless.com. On the morning of 24 February 2022, registered parties will receive an email with a link to the call.

Össur hf: Final Agenda and Proposals for the Annual General Meeting 8 March 2022

Announcement no. 08/2022 22 February 2022 Final agenda and proposals for the Annual General Meeting 8 March 2022 Enclosed is the final agenda and proposals for Össur hf.'s Annual General Meeting to be held on Tuesday 8 March 2022 at 16:00 GMT. The Annual General Meeting will be virtual as previously announced. No changes have been made to the previously announced agenda and proposals. Further information Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com, +354 844 4759 Össur press releases by e-mail If you wish to receive Össur press

Nordstjernan acquires Finnish diagnostics company Aidian

Nordstjernan has signed an agreement to acquire the Finnish in-vitro diagnostics company Aidian from funds that are managed by the Nordic private equity firm Axcel. Aidian is a leading global player in the growing market for point-of-care diagnostics. The company develops, manufactures and sells instruments and tests that are used in such fields as primary care to provide quick and accurate test results. Aidian’s offering of tests addresses several global health problems such as antimicrobial resistance (AMR), diabetes and colorectal cancer. Aidian has tests that are intended to reduce

Year-end report 2021

FOURTH QUARTER 2021 · Revenues amounted to MSEK 390.5 (MSEK 433.7), a decrease by 10 % compared to the same period last year. · Operating profit amounted to MSEK 148.1 (MSEK 79.5), an increase by 86 %. · Profit after financial items amounted to MSEK 147.5 (MSEK 78.6), and profit after tax amounted to MSEK 115.9 (MSEK 59.5). · Cash flow from operating activities amounted to MSEK 269.2 (MSEK 387.1), and cash flow from investing activities amounted to MSEK -213.7 (MSEK -207.3). · By the end of the period cash amounted to MSEK 599.7 (MSEK 767.6). · Earnings per share before

Stayble Therapeutics: Publication of year-end report 2021

Stayble Therapeutics AB (”Stayble” or the ”Company”) published its year-end report for the period January 2021 – December 2021 today. The report (in Swedish) is available as an attached document to this press release and on the Company’s website (Stayble Therapeutics ).Highlights during the fourth quarter (October – December 2021) · Stayble presented interim data from the ongoing phase 2b study and announced that the patient recruitment is still affected by the Covid-19 and that study results can be presented in

Africa Oil to Release Fourth Quarter 2021 Financial Results on February 28, 2022

VANCOUVER, BC, February 22, 2022 /CNW/ (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, “AOC” or the “Company”) will publish its financial and operating results and related management’s discussion and analysis for the three months and twelve months ended December 31, 2021, after Toronto market close on Monday, February 28, 2022. Senior management will hold a conference call to discuss the results on Tuesday, March 1, 2022 at 10:00 (ET) / 16:00 (CET). The conference call may be accessed by dial in or via webcast: Canada +1 647 484 0473North 800-289-0459

Tokmanni Group Corporation: Notice to the Annual General Meeting

Tokmanni Group Corporation        Stock exchange release        22 February 2022 at 9:00 a.m.The shareholders of Tokmanni Group Corporation are hereby invited to the Annual General Meeting to be held on Wednesday 23 March 2022 at 10:00 a.m. at Sanomatalo at the address Töölönlahdenkatu 2, Helsinki, Finland. It will not be possible to participate in the meeting at the meeting venue, but participation will take place in advance in the manner described in this notice. The Board of Directors of the Company has resolved on exceptional meeting procedures based on the so-called temporary act (

NIB in 2021: Strong financials support increase of sustainable finance

In 2021, the disbursement of Nordic Investment Bank’s (NIB’s) long-term lending returned to a more normal level of EUR 2,440 million compared to EUR 4,853 million in 2020, when the Bank paid out a historically high amount in response to the COVID-19 crisis. The net profit for 2021 amounted to EUR 159 million compared to EUR 165 million in 2020. The NIB Board of Directors, which concluded a business strategy review in December 2021, is proposing to distribute EUR 40 million in dividends to the Bank’s Nordic and Baltic member countries.“In 2021, the demand for our long-term financing was

Ponsse’s Financial Statements for 1 January – 31 December 2021

– Net sales amounted to EUR 750.0 (Q1-Q4/2020 636.6) million.– Q4 net sales amounted to EUR 226.6 (Q4/2020 205.2) million.– Operating result totalled EUR 75.0 (Q1-Q4/2020 57.1) million, equalling 10.0 (9.0) per cent of net sales.– Q4 operating result totalled EUR 18.7 (Q4/2020 13.7) million, equalling 8.3 (6.7) per cent of net sales.– Profit before taxes was EUR 73.2 (Q1-Q4/2020 39.6) million.– Cash flow from business operations was EUR 102.4 (74.8) million.– Earnings per share were EUR 1.97 (1.15).– Equity ratio was 60.7 (54.3) per cent.– Order books stood at EUR 439.8 (174.

SAS FORWARD: a new plan as first quarter results are released

For many years SAS has been burdened by an uncompetitive cost structure, that prevents the company from reaching its full potential. Furthermore, the last two years have been the most challenging in the history of the aviation industry and the future remains unpredictable. Travel patterns and market conditions are changing and will have an additional impact on the company. SAS is now, more than ever, in need of a new start. SAS will implement measures aimed at securing long-term competitiveness. Along with the already ongoing work of developing an efficient and profitable business, the

Big gains, big smiles with Planmeca CAD/CAM

Though dental technology has made enormous strides in the 21st century, conventional techniques and technologies remain the mainstream in many markets. At the same time, some doctors are showing the way. One of them is Dr Kennedy Opiyo. Dr Kennedy Opiyo is the owner of the Lake Basin Dental and Orthodontics Center in Nairobi, Kenya, and a longtime CAD/CAM user in a country where the technology has yet to become commonplace. In his clinic, Dr Opiyo harnesses an all-digital CAD/CAM workflow, which includes the Planmeca Emerald™ S intraoral scanner, Planmeca PlanMill® 30 S milling

There are no items matching the current filter
There are no more items matching the current filter
Back to top